CLDX - Celldex Therapeutics, Inc.
After hours:
| Previous Close | 30.37 |
| Open | 30.28 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1000 |
| Day's Range | 30.28 - 31.01 |
| 52 Week Range | 19.85 - 48.40 |
| Volume | |
| Avg. Volume | 631,609 |
| Market Cap | 1.445B |
| Beta (5Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.40 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.33 |
Simply Wall St.Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
GlobeNewswireCelldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
HAMPTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preclinical data from CDX-622, the Company’s bispecific antibody with dual targeting of the alarmin TSLP and stem cell factor (SCF), also known as KIT receptor ligand, developed from its bispecific antibody platform. TSLP and SCF have been shown to contribute to the pathophysiology of various inflammatory, fibrotic and allergic disorders. These data were presented in a poster session as part
ZacksCelldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 1.59% and 157.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Phase 2 CSU enrollment completion expected in Q3 2023 -- Phase 1b CSU study and Phase 1 cholinergic cohort both accepted for oral presentation at EAACI 2023 -- Phase 2 EoE study expected to initiate in June 2023 - HAMPTON, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “This quarter, we were excited to report additional positive data from our barzolvolim
ZacksStrength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?
Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%?
Key Insights Celldex Therapeutics' estimated fair value is US$54.52 based on 2 Stage Free Cash Flow to Equity Celldex...
- GlobeNewswire
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event. About Celldex Therape
- Simply Wall St.
Celldex Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line
Celldex Therapeutics ( NASDAQ:CLDX ) Full Year 2022 Results Key Financial Results Net loss: US$112.3m (loss widened by...
- GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
- Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 - HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update. “Celldex made significant progress over the past year advancing our pipeline. We reported multiple positive data sets from our Phase 1b barzolvolimab program, incl
- GlobeNewswire
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class addition to a historically limited treatment landscape - - At week 12, 56% of all patients in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose groups had complete response and 76% had well-controlled disease (UAS7/UCT) - - At week 24, 53% of all patients in the 1.5 mg/kg and 3.0 mg/kg dose groups had complete response and 70% experienced well
- GlobeNewswire
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company’s Board of Directors. “We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company’s trajectory,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “Dr. Jain’s deep background in drug development strongly complements our Board’s skills and experie
- GlobeNewswire
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chat at the SVB Securities Global Biopharma Conference today at 9:20 am ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechno
- GlobeNewswire
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ETHAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas. Abstracts will be available on the meeting website today, February
- GlobeNewswire
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
- 100% complete response rate in cold urticaria after single dose of barzolvolimab at 1.5 mg/kg, including in omalizumab refractory patients -- Long term follow up of patients with chronic inducible urticaria treated at 3.0 mg/kg confirm that barzolvolimab-induced responses and mast cell suppression are durable and linked -- Company to host webcast conference call on Tuesday, December 6 at 8:00 a.m. ET - HAMPTON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) to
- GlobeNewswire
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
- Includes oral presentation for 1.5 mg/kg cold urticaria cohort - - Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET - HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple presentations from the barzolvolimab development program will be presented at the 6th GA2LEN Global Urticaria Forum (GUF) being held December 7-8 in Berlin, Germany. Abstracts will be available on the meeting website on December 6th
- Simply Wall St.
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
Celldex to Participate in Upcoming November Investor Conferences
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November: Guggenheim 4th Annual Immunology and Neurology Conference on Monday, November 14, 2022 at 2:10 p.m. ETJefferies London Healthcare Conference on Wednesday, November 16, 2022 at 4:45 a.m. ET / 9:45 a.m. GMTEvercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 4:45 p.
ZacksCelldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Multiple clinical-stage programs on track for data updates in upcoming months - HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. “Celldex continued to execute towards our clinical and corporate milestones, making strong progress across multiple programs; importantly, this includes the initiation of our Phase 2 studies in chronic spontaneous a
ZacksSpero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?
Spero Therapeutics, Inc. (SPRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksCelldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “In late June, Celldex reported positive interim data from our ongoing Phase 1b study of barzolvolimab in chronic spontane
- GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.
ZacksWall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?
The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.